EBV BZLF1 190-197 Peptide (HLA-B*08:01) - RAKFKQLL

Applications

The BZLF1 190-197 peptide is one of the most extensively studied EBV-derived CD8+ T-cell epitopes and plays a central role in immune recognition of EBV-infected cells. It is considered an immunodominant epitope in individuals expressing HLA-B*08:01 and is frequently used in:

• ELISpot assays for IFN-Y detection
• Intracellular cytokine staining (ICS)
• Tetramer-based immune monitoring
• Adoptive T-cell therapy research

Due to its strong and reproducible immunogenicity, the RAKFKQLL peptide is widely used as a reference epitope in EBV-specific immune response studies.

Why Choose JPT?

• High expertise in peptide synthesis for immunology research
• Consistent quality and reproducibility
• Optimized for T-cell assays and immunomonitoring
• Trusted partner in viral immunology and oncology research

Custom Antigen Peptide Services

In addition to the EBV BZLF-1 190-197, JPT offers comprehensive custom antigen peptide synthesis services tailored to your research needs.

Researchers can request:

• Custom peptide sequences
• Modified peptides (e.g. phosphorylation, labeling)
• Different purity grades and scales
• Peptides optimized for T-cell assays and immunomonitoring

Our expertise ensures high-quality peptides suitable for immunology, oncology, and infectious disease research.

Scrambled Antigen Peptide Controls

For experimental validation, JPT also provides scrambled versions of antigen peptides, including sequences derived from BZLF1 190-197 (RAKFKQLL).

Scrambled peptides are commonly used as:

• Negative controls in T-cell assays
• Controls for specificity and background signal
• Validation tools in ELISpot, ICS, and cytotoxicity assays

These control peptides help ensure accurate interpretation of EBV-specific immune responses.